Immunomodulators Under Evaluation for the Treatment of COVID-19
Last Updated: December 16, 2021
Summary Recommendations |
---|
The hyperactive inflammatory response to SARS-CoV-2 infection plays a central role in the pathogenesis of COVID-19. See Therapeutic Management of Hospitalized Adults With COVID-19 for the COVID-19 Treatment Guidelines Panel’s (the Panel) recommendations on the use of the following immunomodulators for hospitalized patients according to their disease severity:
There is insufficient evidence for the Panel to recommend either for or against the use of the following immunomodulators for the treatment of COVID-19:
The Panel recommends against the use of the following immunomodulators for the treatment of COVID-19, except in a clinical trial:
The Panel recommends against the use of the following immunomodulators for the treatment of COVID-19:
|
Rating of Recommendations: A = Strong; B = Moderate; C = Weak Rating of Evidence: I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion |